Crossmark

MPT0E028, a pan-HDAC inhibitor, ameliorates bleomycin-induced pulmonary fibrosis by promoting AT2-to-AT1 differentiation through the ATM/AMPK/FoxO1 pathway

Crossref DOI link: https://doi.org/10.1186/s12929-026-01281-8

Published Online: 2026-07-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Chia-Hao

Lee, Hong-Sheng

Liou, Jing-Ping

Cheng, Wun-Hao

Hua, Hung-Sheng

Chen, Bing-Chang

Lin, Chien-Huang
Funding

Funding for this research was provided by:

Taipei Medical University (TMU 106-1200-006-110)
License Information

Text and Data Mining valid from 2026-07-21

Version of Record valid from 2026-07-21
More Information

Article History

Received: 1 August 2025

Accepted: 15 July 2026

First Online: 21 July 2026

Declarations

Ethics approval and consent to participate: The animal study protocols were approved by the Institutional Animal Care and Use Committee of Taipei Medical University (IACUC approval no. LAC-2014-0279).

Consent for publication: Not applicable.

Competing interests: The authors declare no competing interests.

Document is current

Any future updates will be listed below